Hansen Graydon C. 4

4 · STAAR SURGICAL CO · Filed May 12, 2021

Insider Transaction Report

Form 4

Period: 2021-05-11

STAAR SURGICAL COSTAA

Hansen Graydon C.

Sr. VP, Global Operations

Transactions

Exercise/Conversion
Common Stock
2021-05-11$27.53/sh+10,025$275,988→ 25,453 total
Sale
Common Stock
2021-05-12$110.74/sh−5,531$612,503→ 8,847 total
Exercise/Conversion
Common Stock
2021-05-12$29.80/sh+375$11,175→ 9,222 total
Exercise/Conversion
Common Stock Options
2021-05-11−10,025→ 17,737 total
Exercise: $27.53From: 2021-03-20Exp: 2030-03-19→ Common Stock (10,025 underlying)
Exercise/Conversion
Common Stock Options
2021-05-12−348→ 0 total
Exercise: $16.15From: 2019-03-15Exp: 2028-03-14→ Common Stock (348 underlying)
Exercise/Conversion
Common Stock
2021-05-12$16.15/sh+348$5,620→ 9,801 total
Exercise/Conversion
Common Stock Options
2021-05-11−1,050→ 7,272 total
Exercise: $35.98From: 2020-03-14Exp: 2029-03-13→ Common Stock (1,050 underlying)
Exercise/Conversion
Common Stock Options
2021-05-12−375→ 375 total
Exercise: $29.80From: 2019-06-14Exp: 2028-06-13→ Common Stock (375 underlying)
Exercise/Conversion
Common Stock
2021-05-11$35.98/sh+1,050$37,779→ 15,428 total
Sale
Common Stock
2021-05-11$111.61/sh−11,075$1,236,081→ 14,378 total
Exercise/Conversion
Common Stock
2021-05-12$35.98/sh+231$8,311→ 9,453 total
Exercise/Conversion
Common Stock Options
2021-05-12−231→ 7,041 total
Exercise: $35.98From: 2020-03-14Exp: 2029-03-13→ Common Stock (231 underlying)

Footnotes (6)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.08 to $113.18, inclusive.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $112.29, inclusive.
[F3]The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/14/2022.
[F4]The options granted become exercisable as follows: 1/3 on 3/20/2021 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/20/2023.
[F5]The options granted become exercisable as follows: 1/3 on 6/14/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 6/14/2021.
[F6]The options granted become exercisable as follows: 1/3 on 3/15/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/15/2021.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION